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12 months. The chi-square test for trend revealed a 
signiﬁcant trend for a decreasing rate of treatment with
increasing age (p < 0.0001). During the follow-up period,
34% of women had subsequent fractures. Furthermore,
there was a signiﬁcant risk of subsequent fractures with
increasing age (p < 0.0001).
CONCLUSION: Evidence from the published literature
show that the risk of fracture increases with age, partic-
ularly among those with prior fracture events. In this
study, only one-fourth of the study women received osteo-
porotic therapy after an incident bone fracture. Given the
magnitude of the ﬁnancial, physical, and psychosocial
consequences of osteoporotic fractures, more attention
should be given to the treatment of osteoporosis.
ARTHRITIS & OSTEOPOROSIS—Economic
Outcomes Presentations
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OBJECTIVES: To provide a comprehensive assessment 
of the cost-effectiveness of rofecoxib relative to diclofenac
therapy, the main NSAID used in Australia. The evalua-
tion employs cost-utility and cost-effectiveness analysis
from a health system perspective with the endpoints being
the incremental cost per quality adjusted life year (QALY)
gained and incremental cost per life year saved (LYS).
METHODS: A Markov process was used to advance
patients through seven health states in daily cycles over a
period of one year. The modelled population is based on
typical osteoarthritis patients in Australia (approximately
71% women, mean age: 63 years). Clinical data on the
incidence of gastrointestinal adverse events (Perforations/
ulcers/ bleeds or other gastrointestinal adverse events)
were derived by systematic review and meta-analysis of
randomised trials. Utility values were obtained using the
EQ-5D and a survey of health professionals. Resource use
and valuation included drug costs and the costs associ-
ated with the treatment of gastrointestinal adverse events.
Univariate and multivariate sensitivity analysis was
undertaken.
RESULTS: In a mixed population of patients with
osteoarthritis, the incremental cost per QALY associated
with rofecoxib compared to diclofenac is $A18,691.
Simply focusing on mortality, the cost per death avoided
amounts to $A67,092. Assuming that 13.2 discounted life
years would have been saved per death avoided (life
expectancy of typical osteoarthritis patient). The associ-
ated cost per LYS could be as low as $A5,097. Sensitiv-
ity analyses indicated that rofecoxib offers favourable
cost-effectiveness according to Australian National
Health and Medical Research Council (NHMRC) guide-
lines. The maximum incremental cost per QALY gener-
ated when key assumptions were altered in sensitivity
analysis was always less than $A70,000.
CONCLUSIONS: The incremental QALY and LYS out-
comes derived from the modelled evaluation are well
within the bounds considered cost effective by Australian
guidelines. Improved quality of life make rofecoxib a cost
effective alternative for patients with osteoarthritis.
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Osteoarthritis (OA) has an high prevalence rate in 
Italy. Traditional NSAIDs, the commonest symptomatic
OA treatment, cause gastrointestinal (GI) side effects,
varying from milder symptoms of GI intolerance to life-
threatening GI perforation obstruction and bleeding
(POB). Celecoxib has demonstrated a much better GI
safety proﬁle than NSAIDs, but it is more expensive.
OBJECTIVES: To estimate the cost from the Italian
national health service (INHS) perspective of a 12-week
cycle of therapy in OA patients with celecoxib or
NSAIDs.
METHODS: A decision-tree was used to estimate over
12 weeks the costs of two alternative therapies: celecoxib
200mg/day (€1.38/day) and NSAIDs (€0.41/day) whose
cost was calculated as the mean of the ﬁrst ten prescribed
NSAIDs in Italy in year 2000, at the mean dosage. The
time frame was chosen as the most representative of the
Italian physicians prescription habits. Probabilities of side
effects, derived from clinical trials, were: Celecoxib, GI
intolerance 0.078, Anemia 0.0015, Ulcer 0.0085, POB
0.001; NSAIDs, GI intolerance 0.12, Anemia 0.0055,
Ulcer 0.0315, POB 0.008. Probabilities of hospitaliza-
tion, derived from Italian literature, were: GI intolerance,
0; Anemia, 0.2, Ulcer 0.3, POB, 1. Cost to treat the events
were estimated using the INHS tariffs and DRGs and
were: GI intolerance, €138; Anemia without hospitaliza-
tion, €432; anemia with hospitalization, €3,908; Ulcer
without hospitalization, €491, Ulcer with hospitalization,
€2,530; POB, €10,809.34.
RESULTS: The costs of the alternative therapies were
€148.56 for celecoxib 200mg/day and €178.41 for
NSAIDs.
CONCLUSIONS: Celecoxib is more expensive than the
commonest prescribed NSAIDs in Italy; nevertheless,
NSAIDs GI side effect have high prevalence and resource
consumption, included a high rate of hospitalization, and
a related considerable cost load for INHS. Therefore, the
correct prescription of celecoxib may result in global cost-
savings for the payer.
